AIMS/HYPOTHESIS: Brown adipose tissue (BAT) activation increases energy consumption and may help in the treatment of obesity. Cold exposure is the main physiological stimulus for BAT thermogenesis and the sympathetic nervous system, which innervates BAT, is essential in this process. However, cold-induced BAT activation is impaired in obese humans. To explore the therapeutic potential of BAT, it is essential to determine whether pharmacological agents can activate BAT. METHODS: We aimed to determine whether BAT can be activated in lean and obese humans after acute administration of an orally bioavailable sympathomimetic. In a randomised, double-blinded, crossover trial, we administered 2.5 mg/kg of oral ephedrineto nine lean (BMI 22 ± 1 kg/m²) and nine obese (BMI 36 ± 1 kg/m²) young men. On a separate day, a placebo was administered to the same participants. BAT activity was assessed by measuring glucose uptake with [¹⁸F]fluorodeoxyglucose and positron emission tomography-computed tomography imaging. RESULTS:BAT activity was increased by ephedrine compared with placebo in the lean, but unchanged in the obese, participants. The change in BAT activity after ephedrine compared with placebo was negatively correlated with various indices of body fatness. CONCLUSIONS/ INTERPRETATION:BAT can be activated via acute, oral administration of the sympathomimetic ephedrine in lean, but not in obese humans.
RCT Entities:
AIMS/HYPOTHESIS: Brown adipose tissue (BAT) activation increases energy consumption and may help in the treatment of obesity. Cold exposure is the main physiological stimulus for BAT thermogenesis and the sympathetic nervous system, which innervates BAT, is essential in this process. However, cold-induced BAT activation is impaired in obesehumans. To explore the therapeutic potential of BAT, it is essential to determine whether pharmacological agents can activate BAT. METHODS: We aimed to determine whether BAT can be activated in lean and obesehumans after acute administration of an orally bioavailable sympathomimetic. In a randomised, double-blinded, crossover trial, we administered 2.5 mg/kg of oral ephedrine to nine lean (BMI 22 ± 1 kg/m²) and nine obese (BMI 36 ± 1 kg/m²) young men. On a separate day, a placebo was administered to the same participants. BAT activity was assessed by measuring glucose uptake with [¹⁸F]fluorodeoxyglucose and positron emission tomography-computed tomography imaging. RESULTS: BAT activity was increased by ephedrine compared with placebo in the lean, but unchanged in the obese, participants. The change in BAT activity after ephedrine compared with placebo was negatively correlated with various indices of body fatness. CONCLUSIONS/ INTERPRETATION: BAT can be activated via acute, oral administration of the sympathomimetic ephedrine in lean, but not in obesehumans.
Authors: J R Shannon; K Gottesdiener; J Jordan; K Chen; S Flattery; P J Larson; M R Candelore; B Gertz; D Robertson; M Sun Journal: Clin Sci (Lond) Date: 1999-05 Impact factor: 6.124
Authors: Alexander Bartelt; Oliver T Bruns; Rudolph Reimer; Heinz Hohenberg; Harald Ittrich; Kersten Peldschus; Michael G Kaul; Ulrich I Tromsdorf; Horst Weller; Christian Waurisch; Alexander Eychmüller; Philip L S M Gordts; Franz Rinninger; Karoline Bruegelmann; Barbara Freund; Peter Nielsen; Martin Merkel; Joerg Heeren Journal: Nat Med Date: 2011-01-23 Impact factor: 53.440
Authors: Martin Torriani; Kathleen Fitch; Eleni Stavrou; Miriam A Bredella; Ruth Lim; Christina A Sass; Aaron M Cypess; Steven Grinspoon Journal: J Clin Endocrinol Metab Date: 2012-01-18 Impact factor: 5.958
Authors: Wouter D van Marken Lichtenbelt; Joost W Vanhommerig; Nanda M Smulders; Jamie M A F L Drossaerts; Gerrit J Kemerink; Nicole D Bouvy; Patrick Schrauwen; G J Jaap Teule Journal: N Engl J Med Date: 2009-04-09 Impact factor: 91.245
Authors: Andrew L Carey; Renata Pajtak; Melissa F Formosa; Bruce Van Every; David A Bertovic; Mitchell J Anderson; Nina Eikelis; Gavin W Lambert; Victor Kalff; Stephen J Duffy; Martin H Cherk; Bronwyn A Kingwell Journal: Diabetologia Date: 2015-03-01 Impact factor: 10.122
Authors: Aaron M Cypess; Lauren S Weiner; Carla Roberts-Toler; Elisa Franquet Elía; Skyler H Kessler; Peter A Kahn; Jeffrey English; Kelly Chatman; Sunia A Trauger; Alessandro Doria; Gerald M Kolodny Journal: Cell Metab Date: 2015-01-06 Impact factor: 27.287
Authors: B Rachid; S van de Sande-Lee; S Rodovalho; F Folli; G C Beltramini; J Morari; B J Amorim; T Pedro; A F Ramalho; B Bombassaro; A J Tincani; E Chaim; J C Pareja; B Geloneze; C D Ramos; F Cendes; M J A Saad; L A Velloso Journal: Int J Obes (Lond) Date: 2015-05-21 Impact factor: 5.095